Search

Your search keyword '"A. Antonucci"' showing total 101 results

Search Constraints

Start Over You searched for: Author "A. Antonucci" Remove constraint Author: "A. Antonucci" Journal digestive and liver disease Remove constraint Journal: digestive and liver disease
101 results on '"A. Antonucci"'

Search Results

1. Current management of hepatobiliary malignancies between centers with or without a liver transplant program: A multi-society national survey

2. T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK

3. Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: Who is the winner?

4. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

5. Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome

6. Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C

8. Characteristics and management of hepatocellular carcinoma (HCC) in Sicily: first results of the HCC Sicily Multidisciplinary Network

9. OC.09.2 VITAMIN D-RELATED GENETICS AS PREDICTOR OF RESPONSE TO ADALIMUMAB IN CROHN’S DISEASE

11. COVID-19 and intestinal inflammation: Role of fecal calprotectin

12. The best potential treatment for recurrent hepatocellular carcinoma after surgery: a machine learning predictive model for treatment allocation based on an Italian multicentric database

13. COVID-19 and intestinal inflammation: Role of fecal calprotectin

14. The role of postoperative ascites In determining long term survival after curative surgery for hepatocarcinoma: a national multicentric study

15. Care or palliation for recurrent hepatocarcinoma: a multicentric national analysis of survival

16. Care or palliation for recurrent hepatocarcinoma: a multicentric national analysis of survival

17. The role of postoperative ascites In determining long term survival after curative surgery for hepatocarcinoma: a national multicentric study

18. Comparing surgery versus sorafenib in advanced hepatocellular carcinoma: An Italian weighted study

20. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

22. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

24. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

25. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

26. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies

28. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

29. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

30. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

31. Presence of resistance associated variants in patients with virological failure to new direct acting antivirals and requirement of unconventional regimens for re-treatment

34. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

35. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients

36. Different prevalence of HCV resistance and HCV quantification within blood and liver samples (tumoral and non tumoral tissues) of HCC/transplanted patients

37. Involvement of copper in the liver tumorigenesis

38. High Mobility Group Box 1 (HMGB1) and neutrophils an unexpected role in non-alcoholic fatty liver disease: Inhibition of T cell activation and proliferation

39. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

40. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors

43. Clinical relevance of next generation sequencing on baseline detection of minority resistance associated variants in HCV-1 patients treated with protease inhibitors

44. T-09 Correlation between NS5A variants and fibrosis progression in patients with HCV recurrence after liver transplantation

45. OC-24 Genotype analysis, at baseline and early time-points, by population and ultra-deep sequencing in HCV patients treated with BOC/TVR-based therapy

46. Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?

47. Early viral dynamics in HCV-RNA decay and NS3-resistance development predict the risk of failure to first-generation protease inhibitors

48. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT

49. OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE

50. F-34 Maintained long-term suppression of HBV replication in NUC-naïve patients with chronic hepatitis B treated with ETV monotherapy in field practice: The Italian multicenter experience

Catalog

Books, media, physical & digital resources